Complement C9 antibody

Principal name

Complement C9 antibody

Alternative names for Complement C9 antibody

Complement component C9, Complement 9

SwissProt ID

P02748 (Human), P06683 (Mouse), P48747 (Rabit), P48770 (Horse), Q3MHN2 (Bovin), Q62930 (Rat)

Gene ID

735 (C9), 12279, 117512

Available reactivities

Hu (Human), Eq (Equine), Por (Porcine)

Available hosts

Mouse, Rabbit, Goat

Available applications

Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Immunocytochemistry/Immunofluorescence (ICC/IF), Paraffin Sections (P), Functional assay (FN), Frozen Sections (C)

Background of Complement C9 antibody

The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed  the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components.  C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.

General readings

Lint TF, Zeitz HJ, et al. (1980) J. Immunol. 125 (5): 2252–7

  • LinkedIn